Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Schedule of Segment Information

The tables below present segment information reconciled to total Company loss from operations, with segment operating loss including gross profit less direct research and development expenses and direct selling, general and administrative expenses to the extent specifically identified by segment:

	Three Months Ended June 30, 2022
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	2,849		$	35		$	-		$	2,884
Gross margin (loss)		1,407			(46	)		-			1,361
Research and development expenses		205			159			67			431
Depreciation and amortization expense		63			1			-			64
Selling, general and administrative expenses		1,804			184			82			2,070
Total operating expenses		2,072			344			149			2,565
Loss from operations	$	(665	)	$	(390	)	$	(149	)	$	(1,204	)

	Six Months Ended June 30, 2022
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	5,008		$	63		$	-		$	5,071
Gross margin (loss)		2,460			(74	)		-			2,386
Research and development expenses		460			365			184			1,009
Depreciation and amortization expense		114			2			-			116
Selling, general and administrative expenses		3,953			356			109			4,418
Total operating expenses		4,528			722			293			5,543
Loss from operations	$	(2,068	)	$	(796	)	$	(293	)	$	(3,157)

	Three Months Ended June 30, 2021
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	2,190		$	76		$	-		$	2,266
Gross margin		1,215			60			-			1,275
Research and development expenses		305			149			33			487
Depreciation and amortization expense		51			-			-			51
Selling, general and administrative expenses		1,735			96			23			1,854
Total operating expenses		2,091			245			56			2,392
Loss from operations	$	(876	)	$	(185	)	$	(56	)	$	(1,117	)

	Six Months Ended June 30, 2021
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	4,926		$	76		$	-		$	5,002
Gross margin		2,802			60			-			2,862
Research and development expenses		598			268			177			1,043
Depreciation and amortization expense		101			-			-			101
Selling, general and administrative expenses		3,612			196			45			3,853
Total operating expenses		4,311			464			222			4,997
Loss from operations	$	(1,509	)	$	(404	)	$	(222	)	$	(2,135	)